A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

Mark A. Dickson,Manish A. Shah,Dana E. Rathkopf,Archie Tse,Richard D. Carvajal,Nian Wu,Robert A. Lefkowitz,Mithat Gonen,Lauren M. Cane,Heather J. Dials,Gary K. Schwartz

A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

2010

Mark A. Dickson
Manish A. Shah
Dana E. Rathkopf
Archie Tse
Richard D. Carvajal
Nian Wu
Robert A. Lefkowitz
Mithat Gonen
Lauren M. Cane
Heather J. Dials
Gary K. Schwartz

Background The cyclin-dependent kinase inhibitor flavopiridol increases irinotecan- and fluorouracil-induced apoptosis. We conducted a phase I trial of FOLFIRI + flavopiridol in patients with advanced solid tumors.

Keywords:

Phases of clinical research
FOLFIRI
Pharmacology
CDK inhibitor
Cyclin-dependent kinase
Fluorouracil
Camptothecin
Irinotecan
Kinase
Medicine
combination chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations